[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed123", "question_id": "20251201T041413890Z_grok-4-0709_seed123-001", "question": "A 58-year-old man with a history of hypertrophic cardiomyopathy presents with recurrent syncope. Genetic testing reveals a mutation in the MYH7 gene. Echocardiography shows asymmetric septal hypertrophy with a left ventricular outflow tract gradient of 80 mmHg at rest. Despite optimal medical therapy with beta-blockers, he continues to experience symptoms. What is the most appropriate next step in management?", "options": ["Implantable cardioverter-defibrillator placement", "Septal myectomy", "Alcohol septal ablation", "Dual-chamber pacing", "Mavacamten initiation"], "answer": "E", "answer_index": 4, "explanation": "Mavacamten is the most appropriate next step as it is a cardiac myosin inhibitor specifically indicated for symptomatic obstructive hypertrophic cardiomyopathy refractory to beta-blockers, targeting the underlying pathophysiology. Septal myectomy and alcohol septal ablation are invasive options reserved for cases not responding to medical therapy, but mavacamten offers a non-invasive alternative with recent evidence supporting its use before procedural interventions. Implantable cardioverter-defibrillator and dual-chamber pacing address arrhythmic risks but not the outflow obstruction directly.", "generator_model": "grok-4-0709", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues: 58-year-old with HCM (MYH7 mutation), asymmetric septal hypertrophy, resting LVOT gradient 80 mmHg, recurrent syncope despite 'optimal medical therapy with beta-blockers'—these suggest need for advanced management of symptomatic obstructive HCM, but ambiguity in 'optimal' (e.g., includes CCB/disopyramide?) and unspecified syncope etiology (obstructive vs. arrhythmic) fail to drive a unique best answer. Main logical issue(s): Multiple answers defensible as best—A (ICD) for SCD risk in HCM with recurrent syncope (ACC/AHA class 2a), E (mavacamten) for non-invasive obstruction relief per recent guidelines, B (myectomy) as gold-standard invasive therapy for refractory cases with severe gradient; underspecification on prior therapies and syncope workup (e.g., arrhythmia monitoring) enables equal defensibility. Main medical accuracy issue(s): Generally consistent with 2022 ACC/AHA HCM update recommending mavacamten for symptomatic oHCM after beta-blockers/CCB, but overlooks syncope as potential arrhythmic trigger warranting separate SCD risk stratification; 'optimal medical therapy with beta-blockers' is nonstandard phrasing, as optimal typically includes CCB/disopyramide trials. Minimal fix: Revise stem to 'despite beta-blockers, verapamil, and disopyramide, with Holter monitoring showing no arrhythmias and low SCD risk.'\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues: 58-year-old with HCM (MYH7 mutation), asymmetric septal hypertrophy, resting LVOT gradient 80 mmHg, recurrent syncope despite 'optimal medical therapy with beta-blockers'—these suggest need for advanced management of symptomatic obstructive HCM, but ambiguity in 'optimal' (e.g., includes CCB/disopyramide?) and unspecified syncope etiology (obstructive vs. arrhythmic) fail to drive a unique best answer. Main logical issue(s): Multiple answers defensible as best—A (ICD) for SCD risk in HCM with recurrent syncope (ACC/AHA class 2a), E (mavacamten) for non-invasive obstruction relief per recent guidelines, B (myectomy) as gold-standard invasive therapy for refractory cases with severe gradient; underspecification on prior therapies and syncope workup (e.g., arrhythmia monitoring) enables equal defensibility. Main medical accuracy issue(s): Generally consistent with 2022 ACC/AHA HCM update recommending mavacamten for symptomatic oHCM after beta-blockers/CCB, but overlooks syncope as potential arrhythmic trigger warranting separate SCD risk stratification; 'optimal medical therapy with beta-blockers' is nonstandard phrasing, as optimal typically includes CCB/disopyramide trials. Minimal fix: Revise stem to 'despite beta-blockers, verapamil, and disopyramide, with Holter monitoring showing no arrhythmias and low SCD risk.'", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed123", "question_id": "20251201T041413890Z_grok-4-0709_seed123-002", "question": "A 72-year-old woman with Parkinson's disease develops sudden onset of severe headache, vomiting, and left-sided hemiparesis. MRI reveals a right thalamic hemorrhage with intraventricular extension. She is on carbidopa-levodopa and has a history of orthostatic hypotension. What is the most likely underlying mechanism contributing to this event?", "options": ["Cerebral amyloid angiopathy", "Hypertensive vasculopathy", "Levodopa-induced vasospasm", "Orthostatic hypotension-related watershed infarction", "Dopaminergic therapy-associated coagulopathy"], "answer": "B", "answer_index": 1, "explanation": "Hypertensive vasculopathy is the most likely mechanism, as chronic hypertension in elderly patients with Parkinson's often leads to small vessel disease and thalamic hemorrhages. Cerebral amyloid angiopathy typically affects cortical regions, not deep structures like the thalamus. Levodopa does not directly cause vasospasm or coagulopathy, and while orthostatic hypotension is common, it more often results in ischemic rather than hemorrhagic events.", "generator_model": "grok-4-0709", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: U (secondary M). Verdict on keyed answer: Not uniquely determinable. The clinical problem asks for the most likely mechanism of right thalamic hemorrhage in a 72-year-old woman with Parkinson's disease, on carbidopa-levodopa, with orthostatic hypotension. Key stem clues: sudden headache, vomiting, left hemiparesis; MRI showing right thalamic hemorrhage with intraventricular extension; Parkinson's history with orthostatic hypotension and levodopa use—no mention of hypertension or other risk factors. These imply a deep hemorrhagic stroke but lack details like blood pressure or vascular history to pinpoint mechanism. Most likely mechanism per medical knowledge is hypertensive vasculopathy for thalamic bleeds, fitting keyed B. B fits as classic for location; assumes unstated hypertension. Alternatives: A (CAA) worse due to typical cortical involvement, not thalamic; C (levodopa vasospasm) incorrect, no such mechanism; D (orthostatic watershed) wrong as it's ischemic, not hemorrhagic; E (dopaminergic coagulopathy) not established. Main logical issue: Underspecified—missing hypertension history requires assumption for B as unique best, potentially allowing A if amyloid considered in elderly. Main medical accuracy issue: Rationale inaccurately states chronic hypertension is common in Parkinson's (PD more linked to hypotension); teaching point on thalamic ICH as hypertensive is correct but vignette underspecifies. Minimal fix: Add 'poorly controlled hypertension' to patient history in stem.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"U\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (secondary M). Verdict on keyed answer: Not uniquely determinable. The clinical problem asks for the most likely mechanism of right thalamic hemorrhage in a 72-year-old woman with Parkinson's disease, on carbidopa-levodopa, with orthostatic hypotension. Key stem clues: sudden headache, vomiting, left hemiparesis; MRI showing right thalamic hemorrhage with intraventricular extension; Parkinson's history with orthostatic hypotension and levodopa use—no mention of hypertension or other risk factors. These imply a deep hemorrhagic stroke but lack details like blood pressure or vascular history to pinpoint mechanism. Most likely mechanism per medical knowledge is hypertensive vasculopathy for thalamic bleeds, fitting keyed B. B fits as classic for location; assumes unstated hypertension. Alternatives: A (CAA) worse due to typical cortical involvement, not thalamic; C (levodopa vasospasm) incorrect, no such mechanism; D (orthostatic watershed) wrong as it's ischemic, not hemorrhagic; E (dopaminergic coagulopathy) not established. Main logical issue: Underspecified—missing hypertension history requires assumption for B as unique best, potentially allowing A if amyloid considered in elderly. Main medical accuracy issue: Rationale inaccurately states chronic hypertension is common in Parkinson's (PD more linked to hypotension); teaching point on thalamic ICH as hypertensive is correct but vignette underspecifies. Minimal fix: Add 'poorly controlled hypertension' to patient history in stem.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed123", "question_id": "20251201T041413890Z_grok-4-0709_seed123-003", "question": "A 45-year-old man with type 1 diabetes mellitus presents with recurrent hypoglycemia despite dose adjustments. He has a history of autoimmune thyroiditis and vitiligo. Laboratory evaluation shows low morning cortisol and elevated ACTH. What is the most appropriate confirmatory test for the suspected diagnosis?", "options": ["Cosyntropin stimulation test", "Insulin tolerance test", "21-Hydroxylase antibody assay", "Adrenal CT scan", "Metyrapone test"], "answer": "C", "answer_index": 2, "explanation": "21-Hydroxylase antibody assay is the most appropriate confirmatory test for autoimmune adrenalitis in the context of polyglandular autoimmune syndrome type 2, given the patient's other autoimmune conditions. Cosyntropin stimulation test assesses adrenal reserve but does not confirm etiology. Insulin tolerance and metyrapone tests evaluate the hypothalamic-pituitary-adrenal axis but are less specific for autoimmune causes, and adrenal CT is imaging that may show atrophy but not confirm autoimmunity.", "generator_model": "grok-4-0709", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include type 1 diabetes, autoimmune thyroiditis, vitiligo, recurrent hypoglycemia despite adjustments, low morning cortisol, and elevated ACTH, pointing to primary adrenal insufficiency likely due to autoimmune adrenalitis in polyglandular autoimmune syndrome type 2. The question asks for the most appropriate confirmatory test for this suspected autoimmune etiology. Option C (21-Hydroxylase antibody assay) directly confirms autoimmunity against adrenal cortex, fitting the clinical context without requiring assumptions. Alternatives are inferior: A (Cosyntropin) confirms insufficiency but not etiology; B (Insulin tolerance) and E (Metyrapone) assess HPA axis but lack specificity for autoimmunity; D (Adrenal CT) may show atrophy but doesn't confirm autoimmune cause. No main logical issues; stem is consistent, supports unique best answer C matching key, with discriminable options. No main medical accuracy issues; aligns with endocrine guidelines (e.g., Endocrine Society) for diagnosing autoimmune Addison's via autoantibodies in at-risk patients, reflecting current standards without inaccuracies or outdated elements. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include type 1 diabetes, autoimmune thyroiditis, vitiligo, recurrent hypoglycemia despite adjustments, low morning cortisol, and elevated ACTH, pointing to primary adrenal insufficiency likely due to autoimmune adrenalitis in polyglandular autoimmune syndrome type 2. The question asks for the most appropriate confirmatory test for this suspected autoimmune etiology. Option C (21-Hydroxylase antibody assay) directly confirms autoimmunity against adrenal cortex, fitting the clinical context without requiring assumptions. Alternatives are inferior: A (Cosyntropin) confirms insufficiency but not etiology; B (Insulin tolerance) and E (Metyrapone) assess HPA axis but lack specificity for autoimmunity; D (Adrenal CT) may show atrophy but doesn't confirm autoimmune cause. No main logical issues; stem is consistent, supports unique best answer C matching key, with discriminable options. No main medical accuracy issues; aligns with endocrine guidelines (e.g., Endocrine Society) for diagnosing autoimmune Addison's via autoantibodies in at-risk patients, reflecting current standards without inaccuracies or outdated elements. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed123", "question_id": "20251201T041413890Z_grok-4-0709_seed123-004", "question": "A 60-year-old smoker with COPD presents with progressive dyspnea and hemoptysis. CT chest reveals a 2 cm spiculated nodule in the right upper lobe with mediastinal lymphadenopathy. Bronchoscopy with biopsy confirms squamous cell carcinoma. PET-CT shows no distant metastases. What is the most appropriate initial management?", "options": ["Stereotactic body radiotherapy", "Surgical lobectomy with lymph node dissection", "Concurrent chemoradiotherapy", "Immune checkpoint inhibitor monotherapy", "Epidermal growth factor receptor tyrosine kinase inhibitor"], "answer": "B", "answer_index": 1, "explanation": "Surgical lobectomy with lymph node dissection is the most appropriate for stage I squamous cell lung cancer in a patient with adequate pulmonary reserve, offering the best chance for cure. Stereotactic body radiotherapy is an alternative for non-surgical candidates, but this patient has no contraindications mentioned. Chemoradiotherapy and targeted therapies are for more advanced stages or specific molecular profiles not indicated here.", "generator_model": "grok-4-0709", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: U (secondary M)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues that drive (or fail to drive) a unique best answer: Progressive dyspnea, hemoptysis in 60-year-old smoker with COPD; CT showing 2 cm spiculated RUL nodule and mediastinal lymphadenopathy; biopsy-confirmed squamous cell carcinoma; PET-CT with no distant metastases. The mediastinal lymphadenopathy is critical but unclarified (no mention of PET avidity or nodal biopsy), failing to establish definitive stage (I vs III).\\nMain logical issue(s), if any: Underspecified on nodal metastasis status, requiring unstated assumption (e.g., benign vs malignant lymphadenopathy) to determine resectability and best management; this ambiguity allows multiple defensible answers (B for presumed stage I, C for possible stage III).\\nMain medical accuracy issue(s), if any: Keyed answer and rationale erroneously assume stage I and surgical candidacy despite lymphadenopathy suggesting potential N2 disease, contradicting NCCN guidelines for NSCLC staging and management (surgery for confirmed early stage, chemoradiation for locally advanced); overlooks need for mediastinal staging in this context, misleading learners on standard care.\\nMinimal fix: Edit stem to 'PET-CT shows uptake only in the primary nodule with no mediastinal nodal or distant uptake' to confirm N0 status and unambiguously support B as best.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"U\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (secondary M)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues that drive (or fail to drive) a unique best answer: Progressive dyspnea, hemoptysis in 60-year-old smoker with COPD; CT showing 2 cm spiculated RUL nodule and mediastinal lymphadenopathy; biopsy-confirmed squamous cell carcinoma; PET-CT with no distant metastases. The mediastinal lymphadenopathy is critical but unclarified (no mention of PET avidity or nodal biopsy), failing to establish definitive stage (I vs III).\nMain logical issue(s), if any: Underspecified on nodal metastasis status, requiring unstated assumption (e.g., benign vs malignant lymphadenopathy) to determine resectability and best management; this ambiguity allows multiple defensible answers (B for presumed stage I, C for possible stage III).\nMain medical accuracy issue(s), if any: Keyed answer and rationale erroneously assume stage I and surgical candidacy despite lymphadenopathy suggesting potential N2 disease, contradicting NCCN guidelines for NSCLC staging and management (surgery for confirmed early stage, chemoradiation for locally advanced); overlooks need for mediastinal staging in this context, misleading learners on standard care.\nMinimal fix: Edit stem to 'PET-CT shows uptake only in the primary nodule with no mediastinal nodal or distant uptake' to confirm N0 status and unambiguously support B as best.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed123", "question_id": "20251201T041413890Z_grok-4-0709_seed123-005", "question": "A 35-year-old woman in the emergency department presents with chest pain, palpitations, and diaphoresis after using cocaine. ECG shows ST-segment elevation in leads V2-V4. Troponin is elevated. Coronary angiography reveals a thrombus in the left anterior descending artery with no underlying atherosclerosis. What is the most appropriate immediate management?", "options": ["Intracoronary thrombolysis", "Percutaneous coronary intervention with stenting", "Systemic anticoagulation with heparin", "Glycoprotein IIb/IIIa inhibitor infusion", "Aspiration thrombectomy"], "answer": "E", "answer_index": 4, "explanation": "Aspiration thrombectomy is the most appropriate for cocaine-induced myocardial infarction due to vasospasm and thrombus without atherosclerosis, allowing removal of the clot while minimizing vessel trauma. Stenting is unnecessary without plaque, and thrombolysis carries bleeding risks. Anticoagulation and glycoprotein inhibitors are adjunctive but not primary interventions for isolated thrombus.", "generator_model": "grok-4-0709", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recent cocaine use, acute STEMI presentation (chest pain, palpitations, diaphoresis, ST-elevation in V2-V4, elevated troponin), and angiography showing isolated LAD thrombus without atherosclerosis, pointing to cocaine-induced vasospasm and thrombosis requiring targeted clot removal. Main logical issue(s): None; the stem provides sufficient discriminating details (no atherosclerosis) to identify aspiration thrombectomy as the single best immediate management, with alternatives less appropriate due to risks or lack of necessity. Main medical accuracy issue(s): None; aligns with current guidelines for cocaine-associated MI, where aspiration thrombectomy removes thrombus while avoiding unnecessary stenting in non-atherosclerotic vessels, and thrombolysis poses bleeding risks; anticoagulation and GPIIb/IIIa are supportive but not primary. Minimal fix: None required, as the item is unambiguous and accurate; optionally, add 'without vasospasm resolution details' to stem for enhanced clarity, though not essential.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recent cocaine use, acute STEMI presentation (chest pain, palpitations, diaphoresis, ST-elevation in V2-V4, elevated troponin), and angiography showing isolated LAD thrombus without atherosclerosis, pointing to cocaine-induced vasospasm and thrombosis requiring targeted clot removal. Main logical issue(s): None; the stem provides sufficient discriminating details (no atherosclerosis) to identify aspiration thrombectomy as the single best immediate management, with alternatives less appropriate due to risks or lack of necessity. Main medical accuracy issue(s): None; aligns with current guidelines for cocaine-associated MI, where aspiration thrombectomy removes thrombus while avoiding unnecessary stenting in non-atherosclerotic vessels, and thrombolysis poses bleeding risks; anticoagulation and GPIIb/IIIa are supportive but not primary. Minimal fix: None required, as the item is unambiguous and accurate; optionally, add 'without vasospasm resolution details' to stem for enhanced clarity, though not essential.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed123", "question_id": "20251201T041413890Z_grok-4-0709_seed123-006", "question": "A 68-year-old man with atrial fibrillation on anticoagulation develops acute right-sided weakness. CT head shows no hemorrhage, and MRI confirms acute ischemic stroke in the left middle cerebral artery territory. He is within 4.5 hours of symptom onset. What is the most critical factor determining eligibility for intravenous thrombolysis?", "options": ["International normalized ratio value", "Time since last anticoagulant dose", "Presence of atrial fibrillation", "Stroke severity on NIHSS scale", "Reversal agent availability"], "answer": "A", "answer_index": 0, "explanation": "The international normalized ratio value is the most critical, as thrombolysis is contraindicated if INR >1.7 in patients on vitamin K antagonists to avoid hemorrhagic complications. Time since last dose affects coagulopathy but INR directly measures it. Atrial fibrillation and stroke severity influence overall management but not thrombolysis eligibility directly, and reversal agents are for bleeding, not pre-thrombolysis.", "generator_model": "grok-4-0709", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: U (secondary M)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues that drive (or fail to drive) a unique best answer: 68-year-old with atrial fibrillation on unspecified anticoagulation, acute right-sided weakness, CT head no hemorrhage, MRI confirms left MCA ischemic stroke, within 4.5 hours of onset. These suggest potential eligibility for IV thrombolysis, but anticoagulation type is critical for determining the key factor (INR for VKAs vs. time since dose for DOACs), which is missing.\\nMain logical issue(s), if any: The item is underspecified (U) because it omits the type of anticoagulant, requiring an unstated assumption (e.g., VKA for A; DOAC for B) to select a unique best answer. This leads to multiple defensible answers (M), as A and B are equally plausible depending on the assumption, while C, D, and E are less directly relevant to thrombolysis eligibility.\\nMain medical accuracy issue(s), if any: The keyed answer (A) and rationale are accurate per AHA/ASA guidelines for vitamin K antagonists (contraindicated if INR >1.7), but the stem's general 'anticoagulation' includes DOACs, where INR is irrelevant and time since last dose or specific assays are key, introducing clinical inaccuracy without specification.\\nMinimal fix: Add 'on warfarin' to the stem to specify the anticoagulant type, making A unambiguously the best.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"U\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (secondary M)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues that drive (or fail to drive) a unique best answer: 68-year-old with atrial fibrillation on unspecified anticoagulation, acute right-sided weakness, CT head no hemorrhage, MRI confirms left MCA ischemic stroke, within 4.5 hours of onset. These suggest potential eligibility for IV thrombolysis, but anticoagulation type is critical for determining the key factor (INR for VKAs vs. time since dose for DOACs), which is missing.\nMain logical issue(s), if any: The item is underspecified (U) because it omits the type of anticoagulant, requiring an unstated assumption (e.g., VKA for A; DOAC for B) to select a unique best answer. This leads to multiple defensible answers (M), as A and B are equally plausible depending on the assumption, while C, D, and E are less directly relevant to thrombolysis eligibility.\nMain medical accuracy issue(s), if any: The keyed answer (A) and rationale are accurate per AHA/ASA guidelines for vitamin K antagonists (contraindicated if INR >1.7), but the stem's general 'anticoagulation' includes DOACs, where INR is irrelevant and time since last dose or specific assays are key, introducing clinical inaccuracy without specification.\nMinimal fix: Add 'on warfarin' to the stem to specify the anticoagulant type, making A unambiguously the best.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed123", "question_id": "20251201T041413890Z_grok-4-0709_seed123-007", "question": "A 52-year-old woman with acromegaly undergoes transsphenoidal surgery. Postoperatively, she develops polyuria with urine output exceeding 300 mL/hour. Serum sodium is 148 mEq/L, and urine specific gravity is 1.002. What is the most appropriate initial pharmacologic intervention?", "options": ["Desmopressin acetate", "Hydrochlorothiazide", "Demeclocycline", "Tolvaptan", "Conivaptan"], "answer": "A", "answer_index": 0, "explanation": "Desmopressin acetate is the most appropriate for central diabetes insipidus following pituitary surgery, replacing deficient antidiuretic hormone to concentrate urine. Hydrochlorothiazide is used for nephrogenic diabetes insipidus, not central. Demeclocycline and vasopressin antagonists like tolvaptan or conivaptan are for syndrome of inappropriate antidiuretic hormone, which would worsen hypernatremia here.", "generator_model": "grok-4-0709", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues driving unique best answer: 52-year-old with acromegaly (pituitary involvement) post-transsphenoidal surgery, polyuria >300 mL/hour, serum sodium 148 mEq/L (hypernatremia), urine specific gravity 1.002 (dilute urine), indicating central diabetes insipidus (DI) from ADH deficiency. These clues—surgical context, high-output dilute urine, and rising sodium—uniquely support desmopressin as initial therapy to replace ADH and concentrate urine. No main logical issues; stem is consistent, allows discrimination with one defensible best answer (A), and key matches it. Alternatives are inferior: B (hydrochlorothiazide) treats nephrogenic DI, not central; C (demeclocycline), D (tolvaptan), E (conivaptan) are for SIADH/hyponatremia and would exacerbate hypernatremia. No main medical accuracy issues; aligns with standard post-pituitary surgery management per endocrine guidelines (e.g., Endocrine Society), where desmopressin is first-line for central DI. Item is clinically realistic and board-relevant. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues driving unique best answer: 52-year-old with acromegaly (pituitary involvement) post-transsphenoidal surgery, polyuria >300 mL/hour, serum sodium 148 mEq/L (hypernatremia), urine specific gravity 1.002 (dilute urine), indicating central diabetes insipidus (DI) from ADH deficiency. These clues—surgical context, high-output dilute urine, and rising sodium—uniquely support desmopressin as initial therapy to replace ADH and concentrate urine. No main logical issues; stem is consistent, allows discrimination with one defensible best answer (A), and key matches it. Alternatives are inferior: B (hydrochlorothiazide) treats nephrogenic DI, not central; C (demeclocycline), D (tolvaptan), E (conivaptan) are for SIADH/hyponatremia and would exacerbate hypernatremia. No main medical accuracy issues; aligns with standard post-pituitary surgery management per endocrine guidelines (e.g., Endocrine Society), where desmopressin is first-line for central DI. Item is clinically realistic and board-relevant. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed123", "question_id": "20251201T041413890Z_grok-4-0709_seed123-008", "question": "A 55-year-old man with idiopathic pulmonary fibrosis presents with acute worsening dyspnea. High-resolution CT shows new ground-glass opacities superimposed on fibrosis. Bronchoalveolar lavage reveals neutrophilia without infection. What is the most appropriate therapeutic approach?", "options": ["High-dose systemic corticosteroids", "Azathioprine addition to regimen", "Pirfenidone dose escalation", "Nintedanib initiation", "Lung transplantation evaluation"], "answer": "A", "answer_index": 0, "explanation": "High-dose systemic corticosteroids are the most appropriate for acute exacerbation of idiopathic pulmonary fibrosis, aiming to suppress inflammation despite limited evidence. Azathioprine is contraindicated due to increased mortality risk. Pirfenidone and nintedanib are antifibrotics for stable disease, not acute flares, and transplantation is for end-stage but not immediate management.", "generator_model": "grok-4-0709", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute worsening dyspnea in IPF, new ground-glass opacities on HRCT superimposed on fibrosis, and BAL neutrophilia without infection, collectively indicating acute exacerbation of IPF (AE-IPF). These findings support high-dose systemic corticosteroids as the most appropriate therapeutic approach to suppress acute inflammation, aligning with common clinical practice despite limited high-quality evidence. Main logical issue(s): None; the stem provides sufficient details to discriminate A as uniquely best, with alternatives clearly inferior (B contraindicated per PANTHER trial, C and D antifibrotics for chronic management not acute flares, E for end-stage disease not immediate care). Main medical accuracy issue(s): The keyed answer is consistent with mainstream guidelines (e.g., ATS/ERS suggesting glucocorticoids for AE-IPF, though evidence is weak/Grade 2C); however, it lacks nuance on potential harms and absence of strong randomized data, which could mislead on evidence strength. The item's logic correctly contraindicates azathioprine and positions antifibrotics appropriately. Minimal fix: Add to stem or rationale: 'despite weak evidence and potential risks' to emphasize guideline nuance and prevent overconfidence in steroid efficacy.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute worsening dyspnea in IPF, new ground-glass opacities on HRCT superimposed on fibrosis, and BAL neutrophilia without infection, collectively indicating acute exacerbation of IPF (AE-IPF). These findings support high-dose systemic corticosteroids as the most appropriate therapeutic approach to suppress acute inflammation, aligning with common clinical practice despite limited high-quality evidence. Main logical issue(s): None; the stem provides sufficient details to discriminate A as uniquely best, with alternatives clearly inferior (B contraindicated per PANTHER trial, C and D antifibrotics for chronic management not acute flares, E for end-stage disease not immediate care). Main medical accuracy issue(s): The keyed answer is consistent with mainstream guidelines (e.g., ATS/ERS suggesting glucocorticoids for AE-IPF, though evidence is weak/Grade 2C); however, it lacks nuance on potential harms and absence of strong randomized data, which could mislead on evidence strength. The item's logic correctly contraindicates azathioprine and positions antifibrotics appropriately. Minimal fix: Add to stem or rationale: 'despite weak evidence and potential risks' to emphasize guideline nuance and prevent overconfidence in steroid efficacy.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed123", "question_id": "20251201T041413890Z_grok-4-0709_seed123-009", "question": "A 28-year-old man in the emergency department after a motor vehicle collision has hypotension, tachycardia, and abdominal distension. FAST exam shows free fluid in the abdomen. He is taken to the operating room for exploratory laparotomy, revealing a splenic laceration. What is the most appropriate intraoperative management for a hemodynamically unstable patient?", "options": ["Splenic artery embolization", "Partial splenectomy", "Splenorrhaphy with hemostatic agents", "Total splenectomy", "Non-operative management with observation"], "answer": "D", "answer_index": 3, "explanation": "Total splenectomy is the most appropriate for hemodynamically unstable patients with high-grade splenic injury to rapidly control bleeding and stabilize the patient. Embolization and non-operative management are for stable patients. Partial splenectomy or splenorrhaphy preserve splenic function but are time-consuming and risky in instability.", "generator_model": "grok-4-0709", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 28-year-old post-MVC with hypotension, tachycardia, abdominal distension, free fluid on FAST, splenic laceration on laparotomy, and specified as hemodynamically unstable, implying need for rapid bleeding control intraoperatively. These clues point to severe splenic injury causing instability, making total splenectomy the best option for quick hemostasis. Main logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, as instability and intraoperative setting eliminate non-surgical or time-intensive choices. Main medical accuracy issue(s), if any: None; aligns with ATLS and trauma guidelines where total splenectomy is standard for unstable splenic trauma to prevent exsanguination, while alternatives like embolization or observation suit stable patients, and repairs risk ongoing bleeding in instability. The item's logic is current and accurate, though it assumes laceration severity based on presentation, which is typical for board exams. Minimal fix: Add 'high-grade' to 'splenic laceration' in the stem to explicitly match rationale and enhance precision without altering intent.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 28-year-old post-MVC with hypotension, tachycardia, abdominal distension, free fluid on FAST, splenic laceration on laparotomy, and specified as hemodynamically unstable, implying need for rapid bleeding control intraoperatively. These clues point to severe splenic injury causing instability, making total splenectomy the best option for quick hemostasis. Main logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, as instability and intraoperative setting eliminate non-surgical or time-intensive choices. Main medical accuracy issue(s), if any: None; aligns with ATLS and trauma guidelines where total splenectomy is standard for unstable splenic trauma to prevent exsanguination, while alternatives like embolization or observation suit stable patients, and repairs risk ongoing bleeding in instability. The item's logic is current and accurate, though it assumes laceration severity based on presentation, which is typical for board exams. Minimal fix: Add 'high-grade' to 'splenic laceration' in the stem to explicitly match rationale and enhance precision without altering intent.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed123", "question_id": "20251201T041413890Z_grok-4-0709_seed123-010", "question": "A 65-year-old woman with rheumatoid arthritis develops shortness of breath. Echocardiography reveals severe mitral regurgitation with a flail leaflet. She has preserved left ventricular function but elevated pulmonary pressures. Coronary angiography is normal. What is the most appropriate intervention?", "options": ["Mitral valve repair", "Mitral valve replacement with bioprosthesis", "Transcatheter edge-to-edge repair", "Medical management with afterload reduction", "Cardiac resynchronization therapy"], "answer": "A", "answer_index": 0, "explanation": "Mitral valve repair is the most appropriate for severe primary mitral regurgitation due to flail leaflet in a surgical candidate, offering better durability and preservation of ventricular function compared to replacement. Transcatheter repair is for high-risk patients or functional regurgitation. Medical management and resynchronization do not address the structural defect.", "generator_model": "grok-4-0709", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 65-year-old woman with rheumatoid arthritis presents with shortness of breath; echocardiography shows severe mitral regurgitation (MR) with flail leaflet (indicating primary MR), preserved left ventricular function, and elevated pulmonary pressures; normal coronary angiography. These clues point to symptomatic severe primary MR amenable to surgical correction in a patient without evident contraindications to surgery.\\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate a single best intervention without contradictions or underspecification, as no details suggest prohibitive surgical risk.\\nMain medical accuracy issue(s), if any: None; aligns with ACC/AHA guidelines prioritizing mitral valve repair for severe primary MR due to flail leaflet in operable patients, offering better outcomes than replacement or transcatheter options (reserved for high-risk or functional MR). Medical management and resynchronization do not address the structural issue.\\nMinimal fix: No fix needed, though adding 'low surgical risk' to the stem could explicitly reinforce candidacy for repair over transcatheter edge-to-edge repair for absolute clarity.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 65-year-old woman with rheumatoid arthritis presents with shortness of breath; echocardiography shows severe mitral regurgitation (MR) with flail leaflet (indicating primary MR), preserved left ventricular function, and elevated pulmonary pressures; normal coronary angiography. These clues point to symptomatic severe primary MR amenable to surgical correction in a patient without evident contraindications to surgery.\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate a single best intervention without contradictions or underspecification, as no details suggest prohibitive surgical risk.\nMain medical accuracy issue(s), if any: None; aligns with ACC/AHA guidelines prioritizing mitral valve repair for severe primary MR due to flail leaflet in operable patients, offering better outcomes than replacement or transcatheter options (reserved for high-risk or functional MR). Medical management and resynchronization do not address the structural issue.\nMinimal fix: No fix needed, though adding 'low surgical risk' to the stem could explicitly reinforce candidacy for repair over transcatheter edge-to-edge repair for absolute clarity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]